| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
* To whom correspondence should be addressed. E-mail: farid.saad{at}bayerhealthcare.com.
Objective: To study the dose responses of testosterone (T) treatment on sexual dysfunction and the metabolic syndrome two cohorts of elderly men with late onset hypogonadism were followed over 9 months. Patients & methods: Group 1 (28 men; mean age 61 yrs; mean T 2.07 ± 0.50 ng/ml) received the long acting T undecanoate (1000 mg. Group 2 (27 men, mean age 60 yrs, mean T 2.24 ± 0.41) received T gel (50 mg/day) for 9 months. Results: (* statistical significance) With T gel plasma T rose from 2.24 ± 0.41 to 2.95 ± 0.52* at 3 mo, to 3.49 ± 0.89* at 6 mo, to 3.80 ± 0.73 at 9 mo (T at 6 mo* compared to T at 3 mo). With TU plasma T rose from 2.08 ± 0.56 to 4.81 ± 0.83* at 3 mo, to 5.29 ± 0.91 at 6 mo, to 5.40 ± 0.77 at 9 mo. With TU administration plasma T was *higher than with T gel. With TU there was a larger improvement of sexual symptoms (International Index of Erectile Function) and on parameters of the metabolic syndrome. With both treatments, changes in waist circumferences correlated with changes in cholesterol, LDL and HDL. Parameters of safety were not different. Conclusion: T administration has a beneficial effect on sexual dysfunction and on features of the metabolic syndrome in elderly men. The higher plasma levels of T generated with TU than with T gel (50 mg/day) were clearly more effective indicating that there is a plasma level of T / effect relationship.
Key words: Androgen •
Andropause •
Erectile Dysfunction •
Prostate •
metabolic syndrome •
sex hormone binding globulin
This article has been cited by other articles:
 |
|
 |
|
  L. Vignozzi, A. Morelli, E. Sarchielli, P. Comeglio, S. Filippi, I. Cellai, E. Maneschi, S. Serni, M. Gacci, M. Carini, et al. Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit J. Endocrinol., January 1, 2012; 212(1): 71 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Saad, A. Aversa, A. M. Isidori, L. Zafalon, M. Zitzmann, and L. Gooren Onset of effects of testosterone treatment and time span until maximum effects are achieved Eur. J. Endocrinol., November 1, 2011; 165(5): 675 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. R. Cunningham and S. M. Toma Why Is Androgen Replacement in Males Controversial? J. Clin. Endocrinol. Metab., January 1, 2011; 96(1): 38 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Muraleedharan and T. H. Jones Review: Testosterone and the metabolic syndrome Therapeutic Advances in Endocrinology and Metabolism, December 1, 2010; 1(5): 207 - 223. [Abstract] [PDF]
|
|
|
|
 |
|
 A. M. Traish, F. Saad, R. J. Feeley, and A. Guay The Dark Side of Testosterone Deficiency: III. Cardiovascular Disease J Androl, September 1, 2009; 30(5): 477 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. T. Guay The Emerging Link Between Hypogonadism and Metabolic Syndrome J Androl, July 1, 2009; 30(4): 370 - 376. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Traish, A. Guay, R. Feeley, and F. Saad The Dark Side of Testosterone Deficiency: I. Metabolic Syndrome and Erectile Dysfunction J Androl, January 1, 2009; 30(1): 10 - 22. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-A. Cornier, D. Dabelea, T. L. Hernandez, R. C. Lindstrom, A. J. Steig, N. R. Stob, R. E. Van Pelt, H. Wang, and R. H. Eckel The Metabolic Syndrome Endocr. Rev., December 1, 2008; 29(7): 777 - 822. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Kupelian, F. J. Hayes, C. L. Link, R. Rosen, and J. B. McKinlay Inverse Association of Testosterone and the Metabolic Syndrome in Men Is Consistent across Race and Ethnic Groups J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3403 - 3410. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
